CureChat
AI-driven Solutions for Chronic Disease Management
Company Overview
Snapshot
Founded in April 2023 by Shimon Zilbershlag, CureChat operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing AI-driven solutions for chronic disease management.
Business overview
CureChat is a digital health company specializing in AI-driven solutions for chronic disease management. Its core product, Dana, is an AI-powered diabetes assistant designed to provide free, personalized, and medically accurate support based on ADA guidelines. The company focuses on improving diabetes education and accessibility, particularly in emerging markets, while ensuring privacy and compliance with healthcare standards, operating within the Health Tech & Life Sciences sector.
Strategic signal
In August 2024, CureChat's founder, Dr. Shimon Zilbershlag, discussed the innovative Dana Chatbot, highlighting its potential to reimagine diabetes management. This signals the company's commitment to leveraging AI for patient engagement and education, positioning it as a key player in digital healthcare solutions for chronic conditions.
Log in to access full profile ›Company Intelligence Q&A
- What is CureChat's primary focus?
- CureChat specializes in AI-driven solutions for chronic disease management, with a particular emphasis on diabetes education and accessibility.
- When was CureChat founded?
- CureChat was founded in April 2023.
- Who is the founder of CureChat?
- Shimon Zilbershlag is the Founder & CEO of CureChat.
- What is Dana?
- Dana is CureChat's flagship product, an AI-powered diabetes assistant that provides free, personalized, and medically accurate support based on ADA guidelines.
- What was discussed in August 2024 regarding CureChat?
- In August 2024, CureChat's founder, Dr. Shimon Zilbershlag, discussed the innovative Dana Chatbot and its role in reimagining diabetes management.